Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada
Over the years, there have been significant advances in oncology. However, the rate that therapeutics come to market has increased, while the strength of evidence has decreased. Currently, there is limited understanding about how these uncertainties are managed in provincial funding decisions for ca...
Main Authors: | Kristina Jenei, Stuart Peacock, Michael Burgess, Craig Mitton |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/28/4/236 |
Similar Items
-
Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?
by: Rawson NS, et al.
Published: (2017-11-01) -
The role of HTA agencies in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-07-01) -
Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey
by: Julie Polisena, et al.
Published: (2017-05-01) -
Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020-01-01) -
Accelerating patient access to oncology medicines with multiple indications in Europe
by: R. Lawlor, et al.
Published: (2021-01-01)